Patents by Inventor Gregory Driessens

Gregory Driessens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TIGIT Antibodies
    Publication number: 20230190931
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: July 25, 2022
    Publication date: June 22, 2023
    Applicant: iTeos Belgium SA
    Inventors: Anthony COOPER, Christophe QUEVA, Sofie DENIES, Catherine HOOFD, Julia CUENDE, Gregory DRIESSENS, Florence LAMBOLEZ
  • Anti-TIGIT Antibodies
    Publication number: 20230181731
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: September 16, 2022
    Publication date: June 15, 2023
    Applicant: iTeos Belgium SA
    Inventors: Anthony COOPER, Christophe QUEVA, Sofie DENIES, Catherine HOOFD, Julia CUENDE, Gregory DRIESSENS, Florence LAMBOLEZ
  • THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS
    Publication number: 20230121530
    Abstract: The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-?-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.
    Type: Application
    Filed: June 1, 2022
    Publication date: April 20, 2023
    Inventors: Stefano Crosignani, Erica Joke Katelijne Heleen Houthuys, Reece Gerrad Marillier, Chiara Martinoli, Oliver De Henau, Gregory Driessens
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20220306733
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: January 7, 2020
    Publication date: September 29, 2022
    Inventors: Catherine HOOFD, Gregory DRIESSENS, Julia CUENDE
  • Anti-TIGIT antibodies
    Patent number: 11439705
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 13, 2022
    Assignee: ITEOS BELGIUM SA
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
    Patent number: 11376255
    Abstract: The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-?-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: July 5, 2022
    Assignee: iTeos Belgium SA
    Inventors: Stefano Crosignani, Erica Joke Katelijne Heleen Houthuys, Reece Gerrad Marillier, Chiara Martinoli, Oliver De Henau, Gregory Driessens
  • Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
    Patent number: 10945994
    Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 16, 2021
    Assignees: Pfizer Inc., iTEOS THERAPEUTICS
    Inventors: Manfred Kraus, Sandra Cauwenberghs, Stefano Crosignani, Gregory Driessens
  • THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS
    Publication number: 20210069196
    Abstract: The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-?-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.
    Type: Application
    Filed: September 9, 2020
    Publication date: March 11, 2021
    Inventors: Stefano Crosignani, Paul Dickinson, Marcel de Matas, Erica Joke Katelijne Heleen Houthuys, Reece Gerrad Marillier, Chiara Martinoli, Olivier De Henau, Gregory Driessens
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20200407445
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: July 26, 2018
    Publication date: December 31, 2020
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20190315867
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: May 15, 2019
    Publication date: October 17, 2019
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors
    Patent number: 10398679
    Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 3, 2019
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • Anti-TIGIT antibodies
    Patent number: 10329349
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 25, 2019
    Assignee: iTeos Therapeutics SA
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20190100591
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 4, 2019
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julie Cuende, Gregory Driessens, Florence Lambolez
  • TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS
    Publication number: 20180214415
    Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 2, 2018
    Inventors: Stefano CROSIGNANI, Sandra CAUWENBERGHS, Gregory DRIESSENS, Frederik DEROOSE
  • COMBINATIONS COMPRISING A PYRROLIDINE-2,5-DIONE IDO1 INHIBITOR AND AN ANTI-BODY
    Publication number: 20180125817
    Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
    Type: Application
    Filed: May 12, 2016
    Publication date: May 10, 2018
    Inventors: Manfred Kraus, Sandra Cauwenberghs, Stefano Crosignani, Gregory Driessens
  • Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
    Patent number: 9949951
    Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 24, 2018
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
    Patent number: 9758505
    Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: September 12, 2017
    Assignee: iTeos Therapeutics
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
    Patent number: 9603836
    Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula I as IDO1 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: March 28, 2017
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS
    Publication number: 20170035731
    Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 9, 2017
    Inventors: Stefano CROSIGNANI, Sandra CAUWENBERGHS, Gregory DRIESSENS, Frederik DEROOSE
  • NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
    Publication number: 20160263087
    Abstract: 4-(Indol-3-yl)-pyrazole derivative compounds of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof are provided. Further provided is the use of the compounds of Formula I as TDO2 inhibitors. Also provided herein is use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 15, 2016
    Inventors: Stefano Crosignani, Samdra Cauwenberghs, Frederik Deroose, Gregory Driessens